---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032324"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:29:46.742919+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EyePoint appoints Jay Duker as CEO; Nancy Lurker becomes Executive Vice Chair

## Summary
- Effective July 10, 2023, Jay Duker, M.D., promoted from COO/President to President and CEO and appointed to the Board.
- Nancy Lurker transitions to Executive Vice Chair; annual base salary set at $455,000 with target bonus of 45%.
- Duker receives base salary of $650,000, target bonus of 60%, and initial equity grants: 100,000 options + 50,000 RSUs.
- Lurker receives options for 66,666 shares and 33,334 RSUs; she continues as Board member and Vice Chair.
- Transition part of long-term succession plan; Company highlights strong balance sheet and upcoming Phase 2 trial readouts.

## SEC filing metadata
- accession: 0000950170-23-032324
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/eypt-20230710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032324
- JSON: https://secwatch.observer/filing/0000950170-23-032324.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032324.txt

## Key facts
- Executive change
  Jay S. Duker was appointed as President and Chief Executive Officer at EyePoint, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm
- Executive change
  Jay S. Duker was appointed as Director at EyePoint, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Dr. Duker to fill the vacancy for the newly created directorship
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm
- Executive change
  Nancy S. Lurker changed role as Executive Vice Chair at EyePoint, Inc..
  - Action: transitioned
  - Role: Executive Vice Chair
  source text: Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.